Procter & Gamble Health Ltd
Unaudited Financial Results for the Quarter ended June 30, 2026
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 06 Aug 2026, 02:03 PM IST · BSE ID: e5553ca3-463d-48dc-a79f-e03d72769098
View Original BSE Filing (PDF)
💡
In Simple Terms
The company reported its latest quarterly financial results, including an increase in profit due to a property sale.
🤖 AI Summary
- Procter & Gamble Health Ltd. approved Unaudited Financial Results for the quarter ended June 30, 2026.
- Revenue from Operations for the quarter was ₹36,371 Lakhs, with Total Income reaching ₹36,759 Lakhs.
- Net Profit for the period, after exceptional items, stood at ₹9,615 Lakhs.
- An exceptional gain of ₹3,180 Lakhs resulted from the sale of office premises property.
- Basic and Diluted Earnings Per Share (after exceptional items) for the quarter was ₹57.92 per share.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from Operations (Q1 FY27)
36371 Lakhs
7.30
Total Income (Q1 FY27)
36759 Lakhs
7.24
Net Profit for the period (Q1 FY27)
9615 Lakhs
44.97
Exceptional Item (Q1 FY27)
3180 Lakhs
Basic and Diluted EPS (after exceptional items) (Q1 FY27)
57.92
45.27
🏢 How This Affects the Company
The company's primary business segment remains Pharmaceuticals, with no separate segment information provided per Ind AS 108.
Net profit was significantly boosted by an exceptional gain of ₹3,180 Lakhs from property sale, increasing overall profitability for the quarter.
The sale of office premises indicates a change in asset base, but the direct operational impact on current business activities is not specified.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the reported financial performance, including the Basic and Diluted EPS of ₹57.92 (after exceptional items) for the quarter.
🔍
Management Signal
Management reported an exceptional gain from property sale, indicating active asset management and potential capital reallocation.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 results — evaluate core revenue and profit growth without exceptional items.
Updates on utilization of funds from the office premises sale.
Details on any further asset optimization strategies by management.
LOW RISK
No material adverse findings or significant new risks identified in the financial results.
💡 Investor Takeaway
Procter & Gamble Health Ltd.'s Net Profit for Q1 FY27 increased to ₹9,615 Lakhs, largely driven by an exceptional gain of ₹3,180 Lakhs from the sale of office premises. Total Income rose to ₹36,759 Lakhs from ₹34,277 Lakhs in the prior comparable quarter.
⚖️ Strengths & Concerns
✅ Positives
- Net Profit for the period increased to ₹9,615 Lakhs in Q1 FY27, up from ₹8,990 Lakhs in the preceding quarter ended March 31, 2026.
- Total Income for the quarter ended June 30, 2026, was ₹36,759 Lakhs, showing growth from ₹34,277 Lakhs in the corresponding quarter of FY26.
⚠️ Concerns
- Profit before exceptional items and tax for the quarter ended June 30, 2026, was ₹9,731 Lakhs, a decrease from ₹13,321 Lakhs in the preceding quarter.
- Total expenses for the quarter increased to ₹27,027 Lakhs, up from ₹25,396 Lakhs in the corresponding quarter of the previous year.
📅 Company Track Record
In a prior filing on August 6, 2026, Procter & Gamble Health announced Q1 FY27 sales up 7% to ₹356 crores and reported PAT up 45% to ₹96 crores. This current filing details the unaudited financial results, confirming these figures in Lakhs.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Procter & Gamble Health Ltd.'s Net Profit for the quarter ended June 30, 2026?
Procter & Gamble Health Ltd.'s Net Profit for the quarter ended June 30, 2026, was ₹9,615 Lakhs.
What was the Revenue from Operations for Procter & Gamble Health Ltd. in Q1 FY27?
The Revenue from Operations for Procter & Gamble Health Ltd. for the quarter ended June 30, 2026, was ₹36,371 Lakhs.
Did Procter & Gamble Health Ltd. report any exceptional items in Q1 FY27?
Yes, Procter & Gamble Health Ltd. reported an exceptional gain of ₹3,180 Lakhs from the sale of office premises property during the quarter ended June 30, 2026.
What was the Basic and Diluted EPS for Procter & Gamble Health Ltd. in Q1 FY27?
The Basic and Diluted Earnings Per Share (after exceptional items) for Procter & Gamble Health Ltd. for the quarter ended June 30, 2026, was ₹57.92 per share.
Questions based on this BSE filing only. For information purposes.